About us
Mission
Technology
Pipeline
Newsroom
EN
FR
Accueil
>
symediane
Newsroom
All
News
Scientific papers
06.2024
Fabentech announces the launch and first results of first-in-human clinical trial evaluating the safety of its antidote against a deadly plant-based toxin of bioterrorism interest.
News
01.2024
Fabentech awarded €7.7m from the European Commission as coordinator of the e FabRIC consortium to develop an innovative broad-spectrum therapy against emerging viruses with pandemic potential
News
01.2023
Fabentech’s polyclonal antibody technology chosen by the European Commission to counter CBRN threats within the framework of the Counteract consortium
News
01.2023
Potent Neutralizing Activity of Polyclonal Equine Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
Scientific papers
12.2021
Fabentech has been awarded 9.2 million euros to develop its treatment against Covid-19 and its variants
News
03.2021
Bio-production: Fabentech presents its new industrial site
News
02.2021
Sébastien Iva, new CEO of Fabentech
News
07.2020
Fabentech is launching an immunotherapy programme against COVID-19
News
01.2020
Fabentech raises 8.5 million euros to accelerate the development and marketing of its passive immunotherapy treatments
News
07.2019
In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab’)2
Scientific papers
12.2017
Past, present and future therapeutic and prophylactic strategies against arenaviruses responsible of human hemorrhagic fever
Scientific papers
07.2016
Efficacy of a specific polyclonal equine F(ab’)2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir
Scientific papers
02.2015
Fabentech is launching the production of its treatment against Ebola
News
02.2015
Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab’)₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study
Scientific papers
07.2014
Specific polyclonal F(ab’)2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice
Scientific papers
10.2012
Fabentech launches a phase I clinical trial in Singapore for its product against H5N1 avian influenza
News
